Ukrainian children to be immunized by French vaccine Pentaxim

Aug 19, 2016

At the request of the Health Care State Programme of the Ministry of Health (MoH) of Ukraine, the United Nations Development Programme (UNDP) was appointed to source the pentavalent vaccine. The pentavalent vaccine is a combined vaccine with five individual vaccines intended to actively protect against diphtheria, tetanus, acellular pertussis, polio and Haemophilus influenzae type b.

UNDP sourced vaccine of Sanofi Pasteur, the leading manufacturer of this pentavalent vaccine. The vaccine is supplied under the brand name Pentaxim.

Vaccines are extraordinarily complex, requiring on average one to three years to produce. However, global shortages of the pentavalent vaccines containing an acellular Pertussis component arise due to growing demand in a number of countries exceeding the current level of vaccine supply.

In a constrained supply situation and to avoid any impact to the public health programs in Ukraine, UNDP in cooperation with Sanofi Pasteur and the Ukrainian health authorities mobilized efforts to maximize coverage, via a process of re-allocating vaccine doses from one country to another.

All Pentaxim vaccines, regardless of the distribution markets, are produced at Sanofi’s facilities in Lyon, France. The Pentaxim doses initially intended for the Chinese market were consequently delivered from France in bulk to LLC Pharmex Group, Sanofi Pasteur’s authorized manufacturing affiliate in Ukraine for further packaging.  The product’s quality was also confirmed by the Ukrainian Laboratory on Quality Control of Medical Immunobiological Product of the State Expert Center under the Ministry of Health.

During packaging, stickers approved by local health authorities with Ukrainian text were affixed to each unit of supply. The vaccine doses meet the required quality standards.

UNDP Around the world

You are at UNDP Ukraine 
Go to UNDP Global